Get FREE U.S. Shipping on $75 Orders*

Abstract: Cytomegalovirus Disease in the Highly Active Antiretroviral Therapy Era

1 Star2 Stars3 Stars4 Stars5 Stars (46 votes, average: 3.15 out of 5)
Loading...

Curr Infect Dis Rep 2003 Jun;5(3):257-265

Drew WL.

UCSF-Mount Zion Medical Center, Division of Infectious Diseases, 1600 Divisadero Street, Box 1629, Room B201, San Francisco, CA 94115, USA. lawrence.drew@clinlab.ucsfmedctr.org

Cytomegalovirus (CMV) is a major cause of morbidity and mortality in AIDS patients. Epidemiologic studies indicate that until 10 years ago, nearly one half of HIV-infected patients eventually developed CMV end-organ disease, including chorioretinitis, esophagitis, colitis, pneumonia, and central nervous system disease. Since the introduction of highly active antiretroviral therapy (HAART) this incidence has declined dramatically. Nonetheless, patients still present with CMV disease and resistance or intolerance to HAART does develop, which may give rise to a resurgence of CMV syndromes in AIDS patients. Until recently, only intravenous ganciclovir and foscarnet were available for management of CMV infection. With the advent of additional agents, clinicians now face the challenge of optimizing therapy for individual patients. This paper reviews the most common clinical syndromes caused by CMV, the treatment options, as well as an approach to diagnosing and treating antiviral resistance.

PMID: 12760824 [PubMed – as supplied by publisher]

ProHealth CBD Store

 

1 Star2 Stars3 Stars4 Stars5 Stars (46 votes, average: 3.15 out of 5)
Loading...



Leave a Reply